Hypoxia increases tumor cell shedding of MHC class I chain-related molecule: Role of nitric oxide

Cancer Research

Volumn 68, Issue 12, 2008, Pages 4746-4753

  Siemens, D Robert ^a   Hu, Nianping ^a   Sheikhi, Abdol Karim ^b   Chung, Eugene ^a   Frederiksen, Lisa J ^a   Pross, Hugh ^a   Graham, Charles H ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCERYL TRINITRATE; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NITRIC OXIDE; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN RECEPTOR; MHC CLASS I RELATED CHAIN A; MHC CLASS I-RELATED CHAIN A; NATURAL KILLER CELL ACTIVATING RECEPTORS; NITRIC OXIDE DONOR; OXYGEN;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER PATIENT; CYTOLYSIS; DOWN REGULATION; HUMAN; HUMAN CELL; HYPOXIA; MALE; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION; TUMOR GROWTH; ADENOCARCINOMA; ANIMAL; ANOXIA; CELL CULTURE; CYTOLOGY; DRUG SCREENING; IMMUNOSURVEILLANCE; LEUKOCYTE; METABOLISM; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; TUMOR ESCAPE;

ADENOCARCINOMA; ANIMALS; ANOXIA; CELLS, CULTURED; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOLOGIC SURVEILLANCE; INTERLEUKIN-2; LEUKOCYTES; MALE; MICE; MICE, NUDE; NITRIC OXIDE; NITRIC OXIDE DONORS; NITROGLYCERIN; OXYGEN; PROSTATIC NEOPLASMS; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; TUMOR ESCAPE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 49649105571     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-0054     Document Type: Article

References (34)

1. Doubrovina ES, Doubrovin MM, Vider E, et al. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J Immunol 2003;171:6891-9.
2. Gonzalez S, Groh V, Spies T. Immunobiology of human NKG2D and its ligands. Curr Top Microbiol Immunol 2006;298:121-38.
3. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002;419:734-8.
4. Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K, Plymate SR. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest 2004;114:560-8.
5. Postovit LM, Sullivan R, Adams MA, Graham CH. Nitric oxide signalling and cellular adaptations to changes in oxygenation. Toxicology 2005;208:235-48.
6. Sullivan R, Graham CH. Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev 2007;26:319-31.
7. Frederiksen LJ, Sullivan R, Maxwell LR, et al. Chemosensitization of cancer in vitro and in vivo by nitric oxide signaling. Clin Cancer Res 2007;13:2199-206.
8. Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist 2004;9 Suppl 5:10-7.
9. Fink T, Ebbesen P, Koppelhus U, Zachar V. Natural killer cell-mediated basal and interferon-enhanced cytotoxicity against liver cancer cells is significantly impaired under in vivo oxygen conditions. Scand J Immunol 2003;58:607-12.
10. Postovit LM, Adams MA, Lash GE, Heaton JP, Graham CH. Oxygen-mediated regulation of tumour cell invasiveness: involvement of a nitric oxide signalling pathway. J Biol Chem 2002;277:35730-7.
11. Postovit LM, Adams MA, Lash GE, Heaton JP, Graham CH. Nitric oxide-mediated regulation of hypoxia-induced B16F10 melanoma metastasis. Int J Cancer 2004;108:47-53.
12. Matthews NE, Adams MA, Maxwell LR, Gofton TE, Graham CH. Nitric oxide-mediated regulation of chemosensitivity in cancer cells. J Natl Cancer Inst 2001;93:1879-85.
13. Salih HR, Rammensee HG, Steinle A. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 2002;169:4098-102.
14. Waldhauer I, Steinle A. Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res 2006;66:2520-6.
15. Salih HR, Goehlsdorf D, Steinle A. Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients. Hum Immunol 2006;67:188-95.
16. Wiemann K, Mittrucker HW, Feger U, et al. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo. J Immunol 2005;175:720-9.
17. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001;413:165-71.
18. Whorton AR, Simonds DB, Piantadosi CA. Regulation of nitric oxide synthesis by oxygen in vascular endothelial cells. Am J Physiol 1997;272:L1161-6.
19. McCormick CC, Li WP, Calero M. Oxygen tension limits nitric oxide synthesis by activated macrophages. Biochem J 2000;350:709-16.
20. Nathan C, Xie QW. Regulation of biosynthesis of nitric oxide. J Biol Chem 1994;269:13725-8.
21. Louis CA, Reichner JS, Henry WL, Jr., et al. Distinct arginase isoforms expressed in primary and transformed macrophages: regulation by oxygen tension. Am J Physiol 1998;274:R775-82.
22. Hanafy KA, Krumenacker JS, Murad F. NO, nitro-tyrosine, and cyclic GMP in signal transduction. Med Sci Monit 2001;7:801-19.
23. Marten A, Lilienfeld-Toal M, Buchler MW, Schmidt J. Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing γδ T cell cytotoxicity. Int J Cancer 2006;119:2359-65.
24. Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A, Salih HR. Soluble MICA in malignant diseases. Int J Cancer 2006;118:684-7.
25. Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999;285:727-9.
26. Liang BC. Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines. J Neurooncol 1996;29:149-55.
27. Sanna K, Rofstad EK. Hypoxia-induced resistance to doxorubicin and methotrexate in human melanoma cell lines in vitro. Int J Cancer 1994;58:258-62.
28. Teicher BA. Hypoxia and drug resistance. Cancer Metastasis Rev 1994;13:139-68.
29. Cuvier C, Jang A, Hill RP. Exposure to hypoxia, glucose starvation and acidosis: effect on invasive capacity of murine tumor cells and correlation with cathepsin (L + B) secretion. Clin Exp Metastasis 1997;15:19-25.
30. Graham CH, Forsdike J, Fitzgerald CF, Macdonald-Goodfellow S. Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression. Int J Cancer 1999;80:617-23.
31. Vaupel P, Mayer A, Hockel M. Tumor hypoxia and malignant progression. Methods Enzymol 2004;381:335-54.
32. Evans SM, Koch CJ. Prognostic significance of tumor oxygenation in humans. Cancer Lett 2003;195:1-16.
33. Vaupel P, Kelleher DK, Hockel M. Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 2001;28:29-35.
34. Schulz G, Staffileno LK, Reisfeld RA, Dennert G. Eradication of established human melanoma tumors in nude mice by antibody-directed effector cells. J Exp Med 1985;161:1315-25.